FDA is committed to encouraging the event of cannabis-related drug products, including CBD. FDA encourages researchers to request a Pre-Investigational New Drug software (PIND) assembly to discuss questions associated to the event of a selected cannabis-derived and cannabis-associated drug product. This change in the legislation may lead to a extra streamlined process for researchers to […]
